Company: BGLC
Filing Date: 2025-11-07
Form Type: S-3
Source: 0001477932-25-007976
Chunk: 24

Company: BioNexus Gene Lab Corp
Filing Date: 2025-11-07
Form: S-3
Chunk 24
---
 the terms of the Equity Distribution Agreement, we may offer and sell shares of our common stock, no par value, having an aggregate offering price of up to $3,557,000 from time to time through Maxim, acting as our exclusive sales agent, at our discretion.

Our common stock is listed on the Nasdaq Capital Market and trades under the symbol “BGLC”. The last reported sale price of our Common Stock on the Nasdaq Capital Market on November 5, 2025, was $5.39 per share. We are a “smaller reporting company” as defined under the federal securities laws and, as such, have elected to comply with certain reduced reporting requirements for this prospectus supplement and may elect to do so in future filings.

As of the date of this prospectus supplement, the aggregate market value of our outstanding common stock held by non-affiliates is approximately $10,779,582 which is calculated based on 1,796,597 shares of outstanding common stock, of which 1,796,597 shares are held by non-affiliates, and a per share price of $6.00, which was the closing price of our common stock on September 25, 2025, which is the highest closing sale price of our common stock on Nasdaq Capital Market within the prior sixty (60) days of the filing a registration statement of which this prospectus supplement is a part. During the prior twelve calendar month period that ends on and includes the date hereof, the Company did not sell any shares of common stock pursuant to General Instruction I.B.6 to Form S-3.

Sales of our common stock, if any, under this prospectus supplement and accompanying prospectus may be made in sales deemed to be “at the market offerings” as defined in rule 415 promulgated under the Securities Act of 1933, as amended, or the Securities Act. Maxim is not required to sell any specific number or dollar amount of securities but will act as a sales agent using commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreed terms between Maxim and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.

The compensation to Maxim for sales of common stock sold pursuant to the Equity Distribution Agreement will be an amount equal to 2.5% of the gross proceeds of any shares of common stock sold under the Equity Distribution Agreement. In connection with the sale of the common stock on our behalf, Maxim will be deemed to